Latest news

View all

Pharma Business – November 16, 2026

AstraZeneca invests SEK 30 million in obesity research

AstraZeneca is investing just over SEK 30 million in four research projects with Karolinska Institutet and Karolinska University Hospital. The five-year investment covers research on obesity and on kidney and liver disease.

Financing – November 16, 2026

MucoLife gets Vinnova grant for COPD therapy

MucoLife Therapeutics has been granted SEK 1 million by Vinnova, Sweden’s innovation agency, to scale up manufacturing of MLT-001, its inhaled peptide designed to dissolve mucus plugs in the airways of patients with chronic obstructive pulmonary disease (COPD).

Financing – November 16, 2026

Cereno plans SEK 400 million rights issue

Cereno Scientific plans a rights issue of about SEK 400 million to fund its global Phase IIb study EPIMODE with lead candidate CS1 in pulmonary arterial hypertension (PAH). Warrants included in the issue could bring in up to SEK 400 million more, and the company has also secured extended loan financing of up to SEK 175 million from its lender, Fenja Capital.

Science News – November 16, 2026

Reprogrammed tumor cells could boost immunotherapy

An international study led from Lund University shows that cancer cells reprogrammed into immune cells can help organize the immune system’s attack inside tumors. The findings, from experiments in mice, could pave the way for immunotherapies that work for more patients.

Acquisition – November 16, 2026

AstraZeneca acquires Omniose

AstraZeneca has acquired Omniose, an early-stage biotechnology firm developing vaccines against serious ​bacterial infections.

Intellectual Property – November 16, 2026

SynAct nears US patent for resomelagon tablet

SynAct Pharma has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for a patent covering the tablet formulation of resomelagon, its lead drug candidate. Once granted, the patent will protect the clinical dosage form until at least June 2042.

Opinion & debate

Clinical Trials

Clinical Trials – November 10, 2026

Survodutide passes Phase 3 heart safety test

Boehringer Ingelheim’s obesity drug survodutide, licensed from Zealand Pharma, did not increase the risk of major cardiovascular events compared with placebo in the Phase 3 SYNCHRONIZE-CVOT trial. With this result, the registrational SYNCHRONIZE program in obesity is complete.

Clinical Trials – November 9, 2026

Novo’s ziltivekimab fails to cut heart events in full ZEUS data

Full results from Novo’s Phase 3 ZEUS trial confirm that the IL-6 inhibitor ziltivekimab did not reduce the risk of heart attack, stroke or cardiovascular death in people with atherosclerotic cardiovascular disease, chronic kidney disease and inflammation. The data were presented at the American Heart Association’s Scientific Sessions 2026 and published in the New England Journal of Medicine.

Clinical Trials – November 6, 2026

Second Gubra-partnered obesity drug moves into Phase 2

Boehringer Ingelheim has started Phase 2 development of BI 3034701, a potential first-in-class GLP-1/GIP/NPY2 triple receptor agonist partnered with Gubra, triggering a EUR 10 million milestone payment, Gubra said in its third-quarter trading statement. It is the second Gubra-partnered obesity program to reach Phase 2 this year, after AbbVie’s ABBV-295.

Clinical Trials – November 5, 2026

New data supports Herantis’ Phase II design

Finnish Herantis Pharma has extended the placebo-controlled period of its upcoming Phase II study of HER-096 in Parkinson’s disease. The company points to newly published evidence that smartphone-based motor assessments detect disease progression more sensitively than conventional clinical measures.

Clinical Trials – November 4, 2026

Abera cleared for first-in-human trial

Uppsala-based Abera Bioscience has received approval from the Dutch Central Committee on Research Involving Human Subjects (CCMO) to start a Phase I trial of its nasal pneumococcal vaccine candidate Ab-01.12. The approval marks the company’s move from preclinical to clinical development.

Clinical Trials – November 3, 2026

Camurus starts Phase IIb obesity study

Camurus has dosed the first patient in LUNAR-2, a randomized, double-blind, placebo-controlled Phase IIb study of CAM2056, its monthly semaglutide depot, in people with overweight or obesity.

Follow Nordic Life Science news
Follow us on XFollow us on LinkedinFollow us on Bluesky

NLS Insight

Global report – May 26, 2025

Doing business in the world’s new life science powerhouse

In a sector long dominated by the US and Europe, Mainland China is now catching up in global pharma and biotechnology. 

Global report – May 14, 2025

US life sciences under Trump

While reports of federal cutbacks across the US health, life sciences, and research landscapes continue to fuel anxiety among scientists, the situation may not be as dire as people fear, according to one investor.

Sponsored content

Viewlinc Cloud Suite supports life science innovation from laboratory to regulated operations

Vaisala introduces ViewLinc Cloud Suite, a cloud-based environmental monitoring solution that helps organizations start professional-quality monitoring immediately and scale as needs evolve, complemented by Vaisala Care for ViewLinc lifecycle services in selected markets.

Follow Nordic Life Science news
Follow us on XFollow us on LinkedinFollow us on Bluesky

14 EUR
/month

Read the latest issue of our magazine!

Read the latest issue of our magazine!

  • Closer to patients: We follow how putting patients at the center is reshaping life science across the Nordics – from a windswept bike ride across Iceland to negotiating tables where who ultimately gets access to new treatments is decided.
  • Women shaping life science: Exclusive interviews with five women shaping the industry, from executive leaders to scientists. Each shares her personal story, from the events and passions that shaped her career to concrete tips and advice for other women.
  • Business: We have spoken to Björn Odlander, co-founder of HealthCap, about the VC firm’s long-term approach and Europe’s widening capital gap. We have also taken a closer look at Stockholm’s journey to becoming a complete and globally competitive life science ecosystem.
  • In addition: Emma Lundberg shares her insights from conducting world-class cell-mapping science on two continents; we look back on 20 years of Finnish biotech; and we look ahead at our industry’s collective tasks for the next decade.
Subscribe now

Explore topics

Upcoming events

We Value Your Privacy

This site uses cookies

We use cookies to improve your experience on our site. By clicking "accept," you agree to our use of cookies.

Read more about our privacy policy

Only necessary
Accept All
Manage Cookies

Manage Cookies

functional

The "Functional" cookie category includes cookies that are essential for the smooth operation of our website and to enhance your browsing experience. These cookies enable various functionalities that make our site more user-friendly and efficient.

market

The "Market" cookie category encompasses cookies used to analyze and improve our marketing efforts. These cookies help us understand how you interact with our website and provide us with insights to optimize our content and advertisements, ensuring they are relevant to your interests.

personal

The "Personal" cookie category includes cookies that enhance the user experience by storing information about your preferences and interactions on our site. This allows us to tailor content and recommendations to your individual needs, providing a more personalized and engaging experience.